Show simple item record

dc.contributor.authorAlan Dal Pra*
dc.contributor.authorStephane Supiot*
dc.contributor.authorThomas Zilli*
dc.date.accessioned2021-02-11T10:35:08Z
dc.date.available2021-02-11T10:35:08Z
dc.date.issued2018*
dc.date.submitted2018-11-16 17:17:57*
dc.identifier29679*
dc.identifier.issn16648714*
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/44041
dc.description.abstractThe use of radical prostatectomy in patients with high risk of recurrence has significantly increased during the past 10 years. Thus, adjuvant radiation as a part of multimodality treatment or salvage radiation at the evidence of prostate-specific antigen (PSA) progression represents mainstay curative-intent options for a great number of prostate cancer patients. Although, few randomized trials and many retrospective studies have been published, many uncertainties still mold the discussions on the best treatment management for men after prostatectomy. This research topic successfully intended to foster discussions on current controversies in the use of postoperative radiotherapy and to present novel perspectives for treatment optimization.*
dc.languageEnglish*
dc.relation.ispartofseriesFrontiers Research Topics*
dc.subjectR5-920*
dc.subjectRC254-282*
dc.subject.classificationthema EDItEUR::M Medicine and Nursingen_US
dc.subject.otherprostate cancer*
dc.subject.otherPSMA*
dc.subject.otherCholine PET*
dc.subject.otherLH-RH agonists*
dc.subject.othersalvage prostate bed radiotherapy*
dc.subject.otherIntra-operative radiotherapy*
dc.subject.otherrising PSA*
dc.titleControversies and Perspectives in the Use of Postoperative Radiotherapy for Prostate Cancer*
dc.typebook
oapen.identifier.doi10.3389/978-2-88945-450-1*
oapen.relation.isPublishedBybf5ce210-e72e-4860-ba9b-c305640ff3ae*
oapen.relation.isbn9782889454501*
oapen.pages74*


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/